• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CVRx Inc. (Amendment)

    2/2/24 4:52:17 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care
    Get the next $CVRX alert in real time by email
    SC 13G/A 1 s13ga_123123-cvrx.htm SCHEDULE 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549
     
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. 1)1
     
     
    CVRx, Inc.
    (Name of Issuer)
     
     
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
     
    126638105
    (CUSIP Number)
     
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [  ] Rule 13d-1(b)

     

    [  ] Rule 13d-1(c)

     

    [X] Rule 13d-1(d)

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     

     

     
     

     

    CUSIP No. 126638105 Page 2

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

     

    Johnson & Johnson

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [  ]

    (b)       [  ]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New Jersey

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 4,109,336 (1)
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 4,109,336 (1)
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,109,336 (1)
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [   ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 19.2% (2)
    12. TYPE OF REPORTING PERSON CO
             

     

    (1) Consists of (i) 3,495,575 shares held by Johnson & Johnson Innovation-JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson, (ii) 607,725 shares issuable upon exercise of warrants to purchase Common Stock (the “Warrant Shares”) held by Biosense Webster, Inc., a wholly-owned subsidiary of Johnson & Johnson, and (iii) 6,036 shares issuable upon exercise of options to purchase Common Stock (the “Option Shares”) held by Johnson & Johnson Innovation-JJDC, Inc.

    (2) Based on (i) 20,815,635 shares of Common Stock outstanding as of October 24, 2023, as reported in the Issuer’s Report on Form 10-Q for the period ended September 30, 2023 filed with the Securities and Exchange Commission on October 31, 2023, plus (ii) the Option Shares and (iii) the Warrant Shares.

     

     

     

     

     
     

     

    CUSIP No. 126638105 Page 3

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

     

    Johnson & Johnson Innovation-JJDC, Inc.

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [  ]

    (b)       [  ]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 3,501,611 (1)
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 3,501,611 (1)
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,501,611 (1)
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [   ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 16.8% (2)
    12. TYPE OF REPORTING PERSON CO
             

     

    (1) Consists of (i) 3,495,575 shares held by Johnson & Johnson Innovation-JJDC, Inc. and (ii) 6,036 shares issuable upon exercise of options to purchase Common Stock (the “Option Shares”) held by Johnson & Johnson Innovation-JJDC, Inc.

    (2) Based on (i) 20,815,635 shares of Common Stock outstanding as of October 24, 2023, as reported in the Issuer’s Report on Form 10-Q for the period ended September 30, 2023 filed with the Securities and Exchange Commission on October 31, 2023, plus (ii) the Option Shares.

     

     

     

     

     
     

     

    CUSIP No. 126638105 Page 4

     

    AMENDMENT NO. 1 TO SCHEDULE 13G

     

    Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on February 7, 2022 (the “Schedule 13G”). Terms defined in the Schedule 13G are used herein as so defined.

     

    The following Items of the Schedule 13G are hereby amended and restated to read in their entirety as follows:

     

    Item 2(c). Citizenship

     

    J&J: New Jersey

    JJDC: Delaware

     

    Item 4. Ownership

     

    (a) through (c):

     

    The information requested in these paragraphs is incorporated by reference to the cover pages to this Amendment No. 1 to Schedule 13G.

     

     

     

     
     

     

    CUSIP No. 126638105 Page 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 2, 2024

     

     

    JOHNSON & JOHNSON

     

      By: /s/ Marc Larkins
      Name: Marc Larkins
      Title: Secretary
         
         
      JOHNSON & JOHNSON INNOVATION-JJDC, INC.
         
      By: /s/ Jill McManus
      Name: Jill McManus
      Title: Assistant Treasurer

     

     

     

     

     

    Get the next $CVRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVRX

    DatePrice TargetRatingAnalyst
    5/9/2025$7.00Neutral → Underweight
    Analyst
    1/14/2025Mkt Perform → Outperform
    William Blair
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    5/1/2024Outperform → Mkt Perform
    William Blair
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVRx Reports Second Quarter 2025 Financial and Operating Results

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2025 was $12.1 million, an increase of 15% over the prior year quarterActive implanting centers in the U.S. grew to 240, an increase of 27% since June 30, 2024CMS propo

    8/4/25 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

    MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage me

    7/29/25 8:30:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025

    MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, plea

    7/21/25 4:30:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVRx, Inc. downgraded by Analyst with a new price target

    Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

    5/9/25 8:41:10 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx, Inc. upgraded by William Blair

    William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

    1/14/25 7:51:14 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

    Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

    9/10/24 7:46:21 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nielsen Kirk G. bought $59,795 worth of shares (10,966 units at $5.45) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/19/25 6:46:37 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/14/25 5:27:07 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/13/25 7:12:40 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF OPERATING OFFICER Binkowski Brent was granted 16,600 shares (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    8/13/25 4:28:31 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Binkowski Brent

    3 - CVRx, Inc. (0001235912) (Issuer)

    8/13/25 4:27:53 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Nielsen Kirk G.

    4 - CVRx, Inc. (0001235912) (Issuer)

    6/5/25 5:35:50 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Leadership Updates

    Live Leadership Updates

    View All

    CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

    MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and

    6/25/24 6:50:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

    Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe

    1/31/24 8:00:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors

    MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b

    12/20/22 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Financials

    Live finance-specific insights

    View All

    CVRx Reports Second Quarter 2025 Financial and Operating Results

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2025 was $12.1 million, an increase of 15% over the prior year quarterActive implanting centers in the U.S. grew to 240, an increase of 27% since June 30, 2024CMS propo

    8/4/25 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025

    MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, plea

    7/21/25 4:30:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Reports First Quarter 2025 Financial and Operating Results

    MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e

    5/8/25 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by CVRx Inc.

    SC 13D/A - CVRx, Inc. (0001235912) (Subject)

    11/7/24 9:10:51 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by CVRx Inc.

    SC 13G/A - CVRx, Inc. (0001235912) (Subject)

    11/1/24 11:05:15 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by CVRx Inc. (Amendment)

    SC 13G/A - CVRx, Inc. (0001235912) (Subject)

    2/6/24 7:56:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    SEC Filings

    View All

    SEC Form 10-Q filed by CVRx Inc.

    10-Q - CVRx, Inc. (0001235912) (Filer)

    8/5/25 8:31:33 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - CVRx, Inc. (0001235912) (Filer)

    8/4/25 4:13:37 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - CVRx, Inc. (0001235912) (Filer)

    6/5/25 4:16:22 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care